Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249964 · ClinicalTrials.gov registry record · Phase 1
Combination Paclitaxel, Carboplatin and Temozolomide
A Phase 1 study of Cancer and Lung Diseases, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00249964 is a Phase 1 study of Cancer and Lung Diseases that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 15 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00249964, a Phase 1 study of Cancer and Lung Diseases, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to determine the duration of response.
Conditions Studied
Interventions
- DRUG Combination Treatment - Cohort 1
- DRUG Combination Treatment - Cohort 2
- DRUG Combination Treatment - Cohort 3
- DRUG Combination Treatment - Cohort 4
Study Locations (1)
New Mexico
- University of New Mexico Cancer Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249964
The ClinicalTrials.gov registry entry for NCT00249964 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which Combination Treatment - Cohort 1 is the first listed.
NCT00249964 reports 1 study location spanning 1 distinct geographic area - top geographies include New Mexico.
Frequently Asked Questions
What is clinical trial NCT00249964 about?
NCT00249964 is a clinical study titled "Combination Paclitaxel, Carboplatin and Temozolomide". The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to determine the duration of response.
What is the current status of trial NCT00249964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2003-11. Estimated completion is 2011-03.
What conditions does trial NCT00249964 study?
This clinical trial studies the following conditions: Cancer, Lung Diseases.
What interventions are being tested in trial NCT00249964?
The interventions under investigation include: Combination Treatment - Cohort 1 (DRUG), Combination Treatment - Cohort 2 (DRUG), Combination Treatment - Cohort 3 (DRUG), Combination Treatment - Cohort 4 (DRUG).
Who is sponsoring clinical trial NCT00249964?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00249964 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.